Luspatercept Receives Positive EU CHMP Opinion for Treatment of Anemia in Lower-Risk MDS

Luspatercept has been recommended for approval by the EMA for patients with transfusion-dependent anemia and lower-risk myelodysplastic syndromes.

Related Keywords

United States ,Bristol Myers Squibb Reblozyl ,Anne Kerber ,World Health Organization ,European Commission ,European Union ,Bristol Myers Squibb ,Head Of Late Clinical Development ,International Prognostic Scoring System ,European Medicines Agency ,Medicinal Products ,Human Use ,Late Clinical Development ,Cell Therapy ,Revised International Prognostic Scoring System ,Myers Squibb ,Myelodysplastic Syndromes ,Della Porta ,Myeloproliferative Neoplasms ,News ,Mds ,Hematology ,